Does GLASDEGIB Cause Neoplasm progression? 28 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 28 reports of Neoplasm progression have been filed in association with GLASDEGIB (Daurismo). This represents 5.4% of all adverse event reports for GLASDEGIB.
28
Reports of Neoplasm progression with GLASDEGIB
5.4%
of all GLASDEGIB reports
21
Deaths
8
Hospitalizations
How Dangerous Is Neoplasm progression From GLASDEGIB?
Of the 28 reports, 21 (75.0%) resulted in death, 8 (28.6%) required hospitalization, and 3 (10.7%) were considered life-threatening.
Is Neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for GLASDEGIB. However, 28 reports have been filed with the FAERS database.
What Other Side Effects Does GLASDEGIB Cause?
Death (102)
Febrile neutropenia (86)
Pneumonia (50)
Off label use (29)
Neutropenia (26)
Electrocardiogram qt prolonged (18)
Sepsis (18)
Pyrexia (17)
Septic shock (16)
Diarrhoea (14)
What Other Drugs Cause Neoplasm progression?
PALBOCICLIB (10,885)
SUNITINIB MALATE (1,920)
CYCLOPHOSPHAMIDE (1,588)
CARBOPLATIN (1,370)
AXITINIB (1,315)
DOXORUBICIN (1,276)
LETROZOLE (1,225)
PACLITAXEL (1,180)
CRIZOTINIB (1,161)
VINCRISTINE (1,106)
Which GLASDEGIB Alternatives Have Lower Neoplasm progression Risk?
GLASDEGIB vs GLATIRAMER
GLASDEGIB vs GLECAPREVIR\PIBRENTASVIR
GLASDEGIB vs GLEEVEC
GLASDEGIB vs GLICLAZIDE
GLASDEGIB vs GLIMEPIRIDE